[Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine].
BACKGROUND
Argyria, induced by prolonged absorption, is often of professional or medical origin. We report two cases of per cutaneous intoxication with topical silver sulfadiazine.


METHODS
A 64 year-old hypertensive, diabetic woman presented bilateral venous ulcers on the legs. She had applied 100 g of silver sulfadiazine 1 p. 100 cream per week for the past 18 months. Silver concentration in blood high: 38 microgram/l (N<0.5) and led to renal dysfunction, without ocular or hepatic abnormality. A 19 year-old woman was treated with topical silver sulfadiazine for thermic cutaneous burns on legs. Renal and hepatic function was normal but silver concentration in blood was high at 440 microgram/l (N<0) with urinary excretion of silver at 12 microgram/l (N=0).


CONCLUSIONS
Silver, from prolonged and excessive use of topical silver sulfadiazine, deposits in large amounts throughout the body: skin, labial mucosa, gingiva, kidney, liver and cornea. Monitoring concentration of silver in blood and/or urine is necessary, especially in patients treated with silver sulfadiazine cream for cutaneous burns. Indeed, silver is rapidly absorbed through the burn wound. It provokes hepatic, renal and neurologic tissue toxicity. Renal and hepatic function tests are not correlated with serum silver levels.


CONCLUSIONS
The potential for silver toxicity is a direct consequence of applying silver sulfadiazine to extensive burn wounds. Hence monitoring concentrations of silver in blood and/or urine of patients receiving this treatment is recommended.
Maitre
S
S
Service de Dermatologie, CHU de Saint-Etienne, 42055 Saint-Etienne Cedex, France.
Jaber
K
K
Perrot
J L
JL
Guy
C
C
Cambazard
F
F
D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects*; D002056:Burns / Q000188:drug therapy*; D006801:Humans; D007868:Leg Dermatoses / Q000188:drug therapy; D007871:Leg Ulcer / Q000188:drug therapy*; D008875:Middle Aged; D009824:Ointments; D012834:Silver / Q000097:blood* / Q000652:urine*; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D000891:Anti-Infective Agents, Local; D009824:Ointments; D012834:Silver; D012837:Silver Sulfadiazine
Elévation des taux sériques et urinaires d'argent au cours d'un traitement topique par sulfadiazine argentique (Flammazine(R)).